CClinicalTrials.gg
CompletedNCT06079619Updated Apr 5, 2024

Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20

An observational study in Genital Tumor and Pigmented Lesions, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
157
Ages
18 Years and older
Sex
All
01

Study summary

Pigmented lesions of the genital mucosa are common, affecting between 10% and 20% of the population. The clinical appearance is sometimes confusing. They are often extensive, irregular, and inhomogeneous in color, which can make them look suspicious. Moreover, dermatoscopic imaging is often complex to interpret, as shown by the many different patterns reported in the literature.

Thus, preliminary work in confocal microscopy has shown that it is possible to simplify diagnosis by using microscopic, in vivo, non-invasive imaging. However, CIM cameras are rare, very expensive and difficult to access.

Conversely, digital dermatoscopes with 400x magnification are much less expensive and can also allow, in a certain number of cases, an examination at the cellular level of tumors, with, in our opinion, the advantage of being easy to learn. In the context of the pooling of resources within medical centers in particular, their dissemination should accelerate. Furthermore, x400 dermatoscopy can provide similar information to IVCM for the most frequent black genital tumors.

Read the detailed description

The hypothesis that motivates this work is that X400 dermatoscopy in the hands of non-experts would allow a fast increase in their diagnostic capacity by identifying the main genital pigmented tumor, namely melanosis, and thus improve the use of expert centers relieved of the care of benign tumors.

02

Conditions studied

  • Genital Tumor
  • Pigmented Lesions

Keywords

  • dermoscopy
  • non-invasive imaging
  • melanotic macule
  • melanoses
  • mucosa
  • melanoma
  • vulva
  • glans
  • tumor
  • genital tumor
  • nevus
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 578 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men and women with a pigmented lesion of the genital mucosa will be included.

Inclusion criteria

  • Men and women with a pigmented lesion of the genital mucosa, having benefited from a mucosal consultation at the University Hospital of Saint-Etienne, with Professor Perrot.
  • The patient's clinical file must contain clinical images, dermatoscopy images x 20 and at least 1 dermatoscopy image x 400.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
157 participants (actual)
Patient registry
No

Groups and cohorts

  • Group A: expert dermatologists

    Group A is composed of expert dermatologists. Group A doctors will have at their disposal 150 dermoscopic photos, x20 dermatoscopic photos according to the usual practice of pigmented genital tumors. The dermatologists will characterize the dermatoscopy with a standardized reading grid to assess the different dermatoscopic patterns of genital tumors.

    Other: Analysis of photos of pigmented tumours by the three groups

  • Group B: non-dermatologists

    Group B is composed of gynecologists (Group B1) and general practitioners (B2) Group B physicians will only perform dermatoscopy x 400. They will have been given a maximum of 1 hour's training to identify melanosis-type pigmented tumors, which are the most frequent benign tumors in x 400 dermatoscopy. Only three x400 dermatoscopy patterns will be presented to them to the exclusion of all others, which are sufficient to identify benign lesions.

    Other: Analysis of photos of pigmented tumours by the three groups

  • Group C: Artificial intelligence

    Artificial intelligence: the skin Artificial intelligence software, a learning base will be provided, different from the evaluation base and the test base.

    Other: Analysis of photos of pigmented tumours by the three groups

Interventions

  • OtherAnalysis of photos of pigmented tumours by the three groups

    Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.

06

What researchers measure

Primary outcomes

  1. Comparison results between expert dermatologists with x20 dermatoscopic photos (Group A) and non-dermatologists physicians with x400 dermatoscopic photos (Group B)

    Performance of x400 dermatoscopic (results of expert dermatologists versus non-dermatologists physicians)

    Time frame: Year: 1

Secondary outcomes

  1. Comparison results between expert dermatologists with x20 dermatoscopic photos (Group A) and gynecologists with x400 dermatoscopic photos (Group B1)

    Performance of x400 dermatoscopic (results of expert dermatologists versus gynecologists)

    Time frame: Year: 1

  2. Comparison results between expert dermatologists with x20 dermatoscopic photos (Group A) and general practitioners with x400 dermatoscopic photos (Group B2)

    Performance of x400 dermatoscopic (results of expert dermatologists versus general practitioners)

    Time frame: Year: 1

  3. Comparison results between gynecologists with x400 dermatoscopic photos (Group B1) and general practitioners with x400 dermatoscopic photos (Group B2).

    Performance of x400 dermatoscopic (results of gynecologists versus general practitioners)

    Time frame: Year: 1

  4. Comparison results between expert dermatologists with x400 dermatoscopic photos (Group A) and skin Artificial intelligence software with x400 dermatoscopic photos (Group C).

    Performance of x400 dermatoscopic (results of expert dermatologists versus skin Artificial intelligence software)

    Time frame: Year: 1

  5. Comparison results between dermatologists physicians with x400 dermatoscopic photos (Group B) and skin Artificial intelligence software with x400 dermatoscopic photos (Group C).

    Performance of x400 dermatoscopic (results of dermatologists physicians versus skin Artificial intelligence software)

    Time frame: Year: 1

07

Study locations

1 site
  • CHU Saint Etienne
    Saint-Étienne, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06079619
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Mar 1, 2022
Primary completion
Apr 20, 2022
Completion
Apr 20, 2022
Last update
Apr 5, 2024

Study contacts

Jean Luc Perrot, MD PhD
principal investigator · CHU Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion